Skip to content

Edwards Lifesciences

US · EW #442 by market cap Listed 1970
85.78 -0.70 -0.81%
Live - 5344 symbols - heartbeat 411s ago · 2026-10-08 04:00
Pre-market 85.78 0.00%
After-hours 85.78 0.00%
Market cap
49.44B
P/B
4.66
EPS
1.83
Reader sentiment Are you bullish or bearish on EW?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/9/10
  • Jefferies Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $105
    Market Newswire · 2026/9/11
  • BTIG Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/9/11
  • Company notice
    TELA Bio | 4: Statement of changes in beneficial ownership of securities-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
    SEC · 2024/2/17
  • Rating change
    TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $104
    Market Newswire · 2026/7/22
  • Company notice
    TELA Bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-EW Healthcare Partners Fund 2-UGP, LLC(10.44%),EW Healthcare Partners Fund 2-GP, L.P.(10.44%), etc.
    SEC · 2024/10/29
  • William Blair Maintains Edwards Lifesciences(EW.US) With Buy Rating
    Market Newswire · 2026/9/11
  • Rating change
    A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $95 to $110
    Market Newswire · 2026/7/25
  • Rating change
    J.P. Morgan Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $105
    Market Newswire · 2026/7/29
  • Rating change
    BofA Securities Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/7/22
  • Company notice
    TELA Bio | 3/A: Initial statement of beneficial ownership of securities (Amendment)-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
    SEC · 2024/2/17
  • Rating change
    Evercore Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $100
    Market Newswire · 2026/7/6
  • Rating change
    Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Announces Target Price $95
    Market Newswire · 2026/7/16
  • Rating change
    Mizuho Securities Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $105
    Market Newswire · 2026/7/15
  • Company notice
    TELA Bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-EW Healthcare Partners Fund 2-UGP, LLC(16.79%),EW Healthcare Partners Fund 2 GP, L.P.(16.79%), etc.
    SEC · 2024/2/14
  • Company notice
    TELA Bio | 4: Statement of changes in beneficial ownership of securities-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
    SEC · 2025/11/18
  • Rating change
    UBS Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $110
    Market Newswire · 2026/7/28
  • Rating change
    RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $110
    Market Newswire · 2026/7/13
  • Leerink Partners Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/9/29
  • Piper Sandler Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/9/21

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:00:07 · For reference only, not investment advice and not tailored to your situation.